Managing the clinical effects of drug-induced intestinal dysbiosis with a focus to antibiotics: Challenges and opportunities.
Drugs
Dysbiosis
Intestinal
Microbiota
Prevention
Treatment
Journal
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
received:
03
04
2023
revised:
23
06
2023
accepted:
26
06
2023
medline:
15
8
2023
pubmed:
29
6
2023
entrez:
28
6
2023
Statut:
ppublish
Résumé
The term "intestinal dysbiosis" is used for indicating change(s) of the intestinal microbiota which have been associated with the development of diseases and the deterioration of disease treatments in humans. In this review, documented clinical effects of drug-induced intestinal dysbiosis are briefly presented, and methodologies which could be considered for the management of drug-induced intestinal dysbiosis based on clinical data are critically reviewed. Until relevant methodologies are optimized and/or their effectiveness to the general population is confirmed, and, since drug-induced intestinal dysbiosis refers predominantly to antibiotic-specific intestinal dysbiosis, a pharmacokinetically-based approach for mitigating the impact of antimicrobial therapy on intestinal dysbiosis is proposed.
Identifiants
pubmed: 37380062
pii: S0928-0987(23)00140-9
doi: 10.1016/j.ejps.2023.106510
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106510Informations de copyright
Copyright © 2023. Published by Elsevier B.V.